Key facts
- This page summarizes Pamela Garzone's Form 4 filing for Cue Biopharma, Inc. (CUE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Jan 2026, 16:00.
Pamela Garzone - 02 Jan 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)
- Reporting relationship
- Director
- Issuer ticker
- CUE
- Reported as of
- 02 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2026, 16:00:07 UTC
- Prior SEC filing
- 03 Jan 2025
- Next SEC filing
- 28 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Pamela Garzone by Colin Sandercock, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pamela Garzone filed Form 4 for Cue Biopharma, Inc. (CUE) on 06 Jan 2026.
Change
- Previous filing in this sequence was filed on 03 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001974756
Primary reporting owner
Garzone Pamela
- Relationship
- Director
- Address
- C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
- Signature
- /s/ Pamela Garzone by Colin Sandercock, attorney-in-fact
- Signature date
- 06 Jan 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CUE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +24,400
- Change %
- Price
- $0.000000
- Shares after
- 24,400
- Date
- 02 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,400
- Exercise price
- $0.3400
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
Footnote F2
This stock option becomes fully exercisable on the first anniversary of the grant date.